The city of Charlotte, North Carolina, currently has 26 active clinical trials seeking participants for Breast Cancer research studies.
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Recruiting
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
Phase 1b Combo w/ Ribociclib and Alpelisib
Recruiting
This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Atrium Health Levine Cancer Institute, Charlotte, North Carolina
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer, HER2-negative Breast Cancer